VIVUS, Inc. (VVUS)

November 18, 2009

FeaturedProfiles.com Stock Pick: VIVUS, Inc. (VVUS)

Stock Price: $8.57

VIVUS, Inc. is a biopharmaceutical company developing next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women.

We have been following VVUS and we believe now is the time to release it as a stock pick. We believe VVUS is one of the best biopharmaceutical plays out there right now. We believe VVUS is severely undervalued at a market cap of only around $690.30 million.

Keep in mind that this company has two potentially big selling drugs in Qnexa(TM) and Avanafil. VVUS has also grown revenues the past three years from $17.24 million in 2006 to $54.79 million in 2007 to $102.2 million in 2008.

As of their latest quarterly report on September 30th, 2009, VVUS had $226.91 million in cash, cash equivalents and short-term investments.

Qnexa(TM) has shown positive results for reducing weight in various weight classes compared to placebo. The company will be holding a conference call on Wednesday morning for their other major drug candidate at 8:30 AM ET, 11/18 discussing Avanafil Phase 3 results.

VVUS could become a major play with its pipeline and solid fundamentals. VVUS has a 52-week high of $12.88. We believe VVUS has significant upside potential. VVUS seems to have a dedicated following for a company trading under a $1 billion market cap. We could see a major short squeeze with over 10% of its float short.








			November 18, 2009 FeaturedProfiles.com Stock Pick: VIVUS, Inc. (VVUS) Stock Price: $8.57 VIVUS, Inc. is a biopharmaceutical company developing next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. We have been following VVUS and we believe now is the time to release it as a stock pick. We believe VVUS is one of the best biopharmaceutical plays out there right now. We believe VVUS is severely undervalued at a market cap of only around $690.30 million. Keep in mind that this company has two potentially big selling drugs in Qnexa(TM) and Avanafil. VVUS has also grown revenues the past three years from $17.24 million in 2006 to $54.79 million in 2007 to $102.2 million in 2008. As of their latest quarterly report on September 30th, 2009, VVUS had $226.91 million in cash, cash equivalents and short-term investments. Qnexa(TM) has shown positive results for reducing weight in various weight classes compared to placebo. The company will be holding a conference call on Wednesday morning for their other major drug candidate at 8:30 AM ET, 11/18 discussing Avanafil Phase 3 results. VVUS could become a major play with its pipeline and solid fundamentals. VVUS has a 52-week high of $12.88. We believe VVUS has significant upside potential. VVUS seems to have a dedicated following for a company trading under a $1 billion market cap. We could see a major short squeeze with over 10% of its float short.
			DISCLAIMER & RISK DISCLOSURE: FeaturedProfiles.com and SpeculatingStocks.com, Inc. and our affiliates ("our companies") are not registered investment advisers or broker/dealers. Our companies make no commitment that the purchase of securities of companies profiled or otherwise mentioned in our websites are suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the possible lack of liquidity for their securities, investing in such securities is highly speculative and carries a high degree of risk. Never invest based solely on information from this Web site or our email alerts. Our FeaturedProfiles.com Newsletter is our free alert email membership. We profile selected companies on our site. These companies compensate SpeculatingStocks.com, Inc. for profile coverage. This compensation can be found in the disclosure on the bottom of the page of profiles. This Disclaimer & Risk Disclosure is also at the bottom of profiles. Specific questions on membership or profiles can be obtained by writing the FeaturedProfiles.com at: staff@featuredprofiles.com.